- Home
- NML vs ZVRA Comparison
NML vs ZVRA Comparison
Compare NML & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NML
- ZVRA
- Stock Information
- Founded
- NML 2012
- ZVRA 2006
- Country
- NML United States
- ZVRA United States
- Employees
- NML N/A
- ZVRA N/A
- Industry
- NML Finance/Investors Services
- ZVRA Biotechnology: Pharmaceutical Preparations
- Sector
- NML Finance
- ZVRA Health Care
- Exchange
- NML Nasdaq
- ZVRA Nasdaq
- Market Cap
- NML 517.3M
- ZVRA 433.5M
- IPO Year
- NML N/A
- ZVRA 2015
- Fundamental
- Price
- NML $9.03
- ZVRA $7.85
- Analyst Decision
- NML
- ZVRA Strong Buy
- Analyst Count
- NML 0
- ZVRA 8
- Target Price
- NML N/A
- ZVRA $22.29
- AVG Volume (30 Days)
- NML 219.3K
- ZVRA 519.4K
- Earning Date
- NML 01-01-0001
- ZVRA 03-11-2025
- Dividend Yield
- NML 9.75%
- ZVRA N/A
- EPS Growth
- NML N/A
- ZVRA N/A
- EPS
- NML N/A
- ZVRA N/A
- Revenue
- NML N/A
- ZVRA $23,612,000.00
- Revenue This Year
- NML N/A
- ZVRA $281.10
- Revenue Next Year
- NML N/A
- ZVRA $97.98
- P/E Ratio
- NML N/A
- ZVRA N/A
- Revenue Growth
- NML N/A
- ZVRA N/A
- 52 Week Low
- NML $6.09
- ZVRA $4.20
- 52 Week High
- NML $7.33
- ZVRA $9.76
- Technical
- Relative Strength Index (RSI)
- NML 55.45
- ZVRA 47.41
- Support Level
- NML $8.98
- ZVRA $7.78
- Resistance Level
- NML $9.10
- ZVRA $8.33
- Average True Range (ATR)
- NML 0.16
- ZVRA 0.40
- MACD
- NML 0.03
- ZVRA -0.01
- Stochastic Oscillator
- NML 86.15
- ZVRA 45.30
About NML Neuberger Berman Energy Infrastructure and Income Fund Inc.
Neuberger Berman Energy Infrastructure & Income Fund Inc is a closed-end investment management company based in the United States.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.